Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 1, 2019Journal for ImmunoTherapy of CancerOpen Access

Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients

View Full Paper
Ask AI
Bookmark
Share

Authors

SPSarabjot PablaJCJeffrey M. ConroyMNMary Nesline

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Pabla et al. (2019) studied this question.

synapsesocial.com/papers/6a7dc2284776ec633518745fhttps://doi.org/10.1186/s40425-019-0506-3
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The Immune Landscape of Cancer2018 · 6,328 citations
  2. 2FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 12016 · 368 citations
  3. 3The hallmarks of successful anticancer immunotherapy2018 · 600 citations
  4. 4What is better/reliable, mitosis counting or Ki67/MIB1 staining?2016 · 13 citations
  5. 5PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer2016 · 30,894 citations